Our findings showing CREBZF as a NF‐κB coregulator under overnutrition, coupling with the effects of CREBZF on exacerbated hepatic steatosis and NASH, suggest that targeting CREBZF may represent general benefits in treating metabolic diseases. The gene discussed is NFKB1; the disease is Other metabolic disease.